National Institutes of Health - NIH Office of …...Angiogenesis no E-010-2004/2 Modulating P38 Kinase Activity no E-014-2002/0 Neural Crest-Melanocyte cDNA Based Microarray Analysis

National Institutes of Health

Office of Technology Transfer

Biomarker-related Technologies

Available for Licensing

National Institutes of Health (NIH) Office of Technology Transfer

6011 Executive Boulevard, Suite 325 • Rockville MD 20852-3804

Phone: 301-496-7057 • Website: www.ott.nih.gov

http://www.ott.nih.gov/

Technologies Available for Licensing

NIH Office of Technology Transfer

2

INTRODUCTION

NIH has an extensive intellectual property portfolio of early-stage technologies1 and also

invests substantially in their development. Roughly 10 percent of the annual NIH budget

is dedicated to intramural research and development activities -- resulting in inventions

that form the basis of a variety of new medical technology and therapies in the areas of

medical devices, software, vaccines, diagnostics, and reagents. Similar to university

research, commercial partners are needed to make sure that the long hours at the lab

bench and the public investment pay off in the end in marketed products.

NIH believes that innovative, early stage companies can play a significant role in the

future development of leading-edge research. While the increasingly consolidated

pharmaceutical industry remains a steady customer of research reagents and clinical

collaborations with NIH, the more exciting therapeutic developments increasingly seem

to come from NIH licenses signed with small and medium-sized life science companies

early in their growth phase.

To further attract such early-stage concerns and start-ups, NIH affords creative treatment

to small firms and tries to provide IP agreements that facilitate new areas of product

development based upon NIH research. For example, financially-burdened smaller

companies can benefit from flexibility on patent costs and license execution fees in

license agreements. Of particular note for venture-backed firms is that companies do not

give up equity or management control nor are their future development or marketing

rights compromised by signing NIH license agreements. Finally, once the product is in

development, NIH has the capability to assist with clinical trials, follow-on research

collaborations, and even eventual purchase of the product as a customer.

We have collected some medical technologies your company might be interested in for

further discussion with our licensing managers.

Once you have picked the technology of interest, we urge you to apply for a License. A

copy of the License Application template can be found at the NIH OTT website at:

http://www.ott.nih.gov/forms_model_agreements/forms_model_agreements.aspx

1 The NIH Office of Technology Transfer cannot guarantee that the listed technologies are still

available for licensing. Please contact the Licensing and Patenting Manager (listed under each

technology) for the current status and for other complementary technologies.

http://www.ott.nih.gov/forms_model_agreements/forms_model_agreements.aspx



3

TABLE OF CONTENTS

Internal Medicine Biomarker-related Technologies Page 4

Infectious Disease Biomarker-related Technologies Page 10

Cancer Biomarker-related Technologies Page 14



4

Internal Medicine Biomarker-related Technologies

HHS Ref. No. Invention Title Claimed DNA?

E-005-2004/0 Methods for the Selection of Subjects for Multiple Sclerosis Therapy yes

E-008-2008/0 Diagnosis and Treatment of Barrett's Esophagus and Associated Esophageal Adenocarcinoma

no

E-009-1996/0 Methods And Compositions For Inhibiting Inflammation And Angiogenesis

no

E-010-2004/2 Modulating P38 Kinase Activity no

E-014-2002/0 Neural Crest-Melanocyte cDNA Based Microarray Analysis for Human Skin Pigmentation Research

yes

E-018-2009/0 Biomarkers for Sjögren's Syndrome no

E-020-2003/0; E-020-2003/1

LMNA Gene and Its Involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and Arteriosclerosis

yes

E-027-2006/0 PDE11A as a Novel Therapeutic Target for Inherited Form of Cushing Syndrome and Endocrine Tumors

yes

E-030-1996/0 A Method For Imaging Nicotinic Acetylcholinergic Receptors In The Brain Using Radiolabeled Pyridyl 7-Azabicycloheptanes

no

E-037-2003/0; E-037-2003/1

Method for the Diagnosis and Treatment of Vascular Disease no

E-041-2005/0 Methods for Detecting Progression of Low Grade Cervical Dysplasia yes

E-042-2006/0 Complement Regulatory Gene Variants as Predictive Tests for Age-related Macular Degeneration (AMD)

yes

E-049-2008/0 Cripto-1 as a Biomarker for Cardiac Ischemia no

E-054-2000/0 Use and Targeting of CD98 Light-Chain Proteins in Therapies for Thyroid Hormone Disorders

no

E-057-2005/0 Novel Glycated Peptides and Proteins as Biomarkers for Diabetes Control

no

http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=1050


























5

E-061-1998/0 Polymorphic Human GABAA Receptor a-6 Subunit yes

E-064-2005/0 Biomarkers for Tissue Status no

E-075-2003/0 Use of Cripto-1 as a Biomarker for Neurodegenerative Disease and Method of Inhibiting Progression Thereof

no

E-075-2008/0 Cripto-1 Represents a Biomarker for Chronic Inflammatory Diseases no

E-076-1998/0 Genetic Polymorphisms Of Interleukin-1 Alpha And Beta Associated With Early Onset Periodontitis

yes

E-077-1999/0 Monoclonal Antibodies (MAbs) Define Human Cytochrome P450 Drug Metabolism

no

E-079-1993/0 Methods for Diagnoses and Treatment of XSCID yes

E-083-1990/0 Macrophage Stimulating Protein no

E-084-1991/1 Antibodies and Polypeptides Specific to AAMP-1: Diagnostic and Therapeutic Uses Thereof

no

E-084-2009/0 Genetic Mutations Associated with Stuttering yes

E-088-2007/0 Zscan4: A Gene Critical for Early Embryonic Development yes

E-091-1998/0 Method for Non-Invasive Identification of Individuals at Risk for Diabetes

no

E-092-2004/0 Anti-Marinobufagenin Antibodies and Methods for Their Use no

E-112-1999/0 Method For Detecting Radiation Exposure no

E-114-2004/0 Multi-Domain Amphipathic Helical Peptides and Methods of Their Use

no

E-122-1997/0 Genes For Niemann-Pick Type C Disease yes

E-123-1999/0 PTH2 and PTH1 Receptor Ligands no


























6

E-128-2004/0; E-128-2004/1

Cytonectin, Cytonectin Gene and Cytonectin Inhibitors and Binding Ligands and Their Use in the Diagnosis and Treatment of Disease

yes

E-137-1990/0 Monoclonal Antibodies Specific for Human Thymidylate Synthase no

E-149-2005/0 Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease

yes

E-152-2002/0; E-152-2002/1

Quantitative Assay of the Angiogenic and Antiangiogenic Activity of a Test Molecule

no

E-156-1996/0 Rapid Method For Diagnosing The Various Forms Of Alpha-Thalassemia

yes

E-157-1994/1 Method and Composition for Detecting Dihydropyrimidine Dehydrogenase Splicing Mutations

yes

E-157-2006/0 Predictive Diagnostic Test for Anti-Depressant Related Suicide Risk yes

E-163-2002/2 Diagnostics and Therapeutics for Hydrocephalus yes

E-168-2001/0; E-168-2001/1

TMC1, a Deafness-Related Gene yes

E-170-2000/0 NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties

yes

E-171-2009/0 Improved Antibodies Against ErbB4/Her4 no

E-173-1998/0 Assay for the Detection of a Variety of Tumors in Biological Specimens

no

E-174-2000/0 Effect of COMT Genotype on Frontal Lobe Function yes

E-181-1998/0 A Mitochondrial-Specific ATP-Binding Transporter Gene (ABC7) Is An Iron Transporter In An Inherited Ataxia-Anemia Syndrome

yes

E-181-2005/1 Impaired Neuregulin1-stimulated B Lymphoblast Migration as Diagnostic for Schizophrenia

no

E-184-1995/0; E-184-1995/1

Materials And Methods For Detection And Treatment Of Insulin Dependent Diabetes

no

E-190-1997/0 Cloning Of A Gene Mutation For Parkinson's Disease yes






























7

E-196-2006/0 Diagnosis and Prognosis of Fabry Disease by Detecting Neuronal Apoptosis Inhibitor Protein (NAIP) Expression

no

E-197-2006/0 Differential Expression of Molecules Associated with Intra-Cerebral Hemorrhage

no

E-207-2006/0 Novel Monoclonal Antibody Microarray no

E-219-2008/0 Method for the Diagnosis and Prognosis of Age-Related Cardiovascular Disorders

no

E-221-1989/0; E-221-1989/1

Novel Epidermal Growth Factor Receptor (ErbB-3) And Antibodies yes

E-231-2005/0 In Vivo Non-Invasive Diagnostic Method Using Magnetic Resonance Spectroscopy of Aspartate Transaminase

no

E-239-2000/0 A Fertility Test to Detect Ovarian Autoimmune Disease Using Human Recombinant MATER Protein

yes

E-244-2004/0 The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof

no

E-245-2006/0 Novel Isoform of KCNH2 for the Treatment of Schizophrenia yes

E-247-2001/0 Methods of Diagnosing and Treating Schizophrenia yes

E-257-1997/0 Identification Of The Gene Causing Familial Mediterranean Fever yes

E-257-1999/0 Methods and Compositions for Correlating CCR5 Expression with Essential Hypertension

yes

E-258-2005/0 Method for Determining Redox Status of a Tissue no

E-262-2000/0; E-262-2000/1

SH2 Domain Binding Inhibitors no

E-263-2003/0 Immunogenic T Cell Targets in Autoimmune Hepatitis and Methods of Use

no

E-276-2004/0 Methods for Diagnosis of Atherosclerosis no

E-285-2006/2 New Tumor Endothelial Markers: Genes that Distinguish Physiological and Pathological Angiogenesis

no





























8

E-289-1988/2 Evaluative Means For Detecting Inflammatory Reactivity no

E-301-2006/0 New High-Throughput and Bioinformatic Tools to Identify and Use Genomic DNA Sequence Dimorphisms (Indels)

yes

E-306-2003/0 Genetic Fingerprint of Acute Stroke no

E-312-2006/0 Latrophilin 3, a Gene Involved in Attention Deficit Hyperactivity Disorder

yes

E-328-2007/0 Identification of Persons Likely to Benefit from Statin Mediated Cancer Prevention by Pharmacogenetics

yes

E-354-2004/1 Proteomic Profiles Associated with Aging no

E-241-2005 Transgenic Mice in which the Gene for MCP-1 is Deleted no

E-193-1997 Targeted Recombinant Adenoviral Vectors yes

E-084-2009 Genetic Mutations Associated with Stuttering no

E-223-2006 E-284-2008

Small-Molecule TSH Receptor Modulators for Diagnosis and Treatment of Thyroid Disease and Cancer

no

E-312-2008 Cell Based Immunotherapy no

E-187-2007 Indoline Compounds for the Treatment of Spinal Muscular Atrophy (SMA) and Other Diseases

no

E-140-2008 Species-Independent A3 Adenosine Receptor Agonists no

E-129-2008 Synthetic Analogs of Juxtamembrane Domain of IGF-1 Receptor as Anti-Cancer Agents

no

E-154-2007 VEGF-B as a Therapeutic Agent for Neurodegenerative Disease no

E-217-2007 N-Acetyl Mannosamine as a Therapeutic Agent no

E-172-2007 Collagen-Induced Platelet Aggregation Inhibitor from Mosquito Salivary Glands

no



























9

E-108-2007 Photosensitization by Nuclear Receptor-Ligand Complexes and Cell Ablation Uses Thereof

no

E-012-2009 A Method of Identifying Cdk5/p35 Modulators, and Possible Diagnostic or Therapeutic Uses for Neurodegenerative Diseases

no

E-219-2007 E-219-2007

Dendrimer Conjugates Targeting Adenosine Receptors, P2Y Receptors and Other Receptors of the GPCR Superfamily, for Use in the Treatment of Various Disorders, Including Neurodegenerative Diseases, Stroke, Epilepsy, Pain and Thrombosis

no

E-295-2008 Novel Inhibitor of NF-kappa B Pathway no

E-021-2007 Automated Method for Rapid Detection of Sickle Cell Disease Inhibitors

no

E-140-2008 Species-Independent A3 Adenosine Receptor Agonists no

E-075-2008 Cripto-1 Represents a Biomarker for Chronic Inflammatory Diseases no

E-049-2008 Cripto-1 as a Biomarker for Cardiac Ischemia no

E-259-2007 Nitrite and Nitrite-Methemoglobin Therapy to Detoxify Stroma-Free Hemoglobin Based Blood Substitutes

no

E-222-2009 RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses

no

E-270-2009 Immortalized Transformed Lymphoblastoid Cell Lines from Patients with François-Neetens Mouchetée Fleck Corneal Dystrophy (CFD)

no

E-002-2008 Modulators of Pregnane X Receptor (PXR) as Therapeutics for Bowel Disorders (BD)

no

E-123-2009 Mouse Monoclonal Antibodies to Human Tristetraprolin (TTP) no

E-046-2009 E-047-2007

Knockout of Aryl Hydrocarbon Receptor (AhR) and its Binding Partner Aryl Hydrocarbon Receptor Nuclear Translocator (Arnt) each in Separate Mouse Models

no

E-263-2009 Small-Molecule Inhibitors of Angiogenesis no






























10

Infectious Disease Biomarker-related Technologies


E-003-1989/0 Nucleotide And Amino Acid Sequences Of The Four Variable Domains Of The Major Outer Membrane Proteins Of Chlamydia Trachomatis

yes

E-004-2005/0 Human Monoclonal Antibodies Against Hendra and Nipah Viruses no

E-008-1996/0 C-C Chemokines That Inhibit Retrovirus Infection yes

E-010-2004/2 Modulating P38 Kinase Activity no

E-019-1993/0 Parvovirus B19 Receptor And Parvovirus B19 Detection no

E-032-1990/1 Method For Immune Capture And Primary Isolation Of Borrelia Burgdorferi

no

E-032-1994/0 Nucleotide And Deduced Amino Acid Sequences Of The Envelope-1 And Core Genes Of Isolates Of Hepatitis C Virus And Methods Of Use

yes

E-034-1989/0 Probe To Identify Enteroinvasive E. coli And Shigella Species yes

E-049-2004/0 Anti-Plasmodium Compositions and Methods of Use no

E-054-1997/0; E-055-1997/0

Monoclonal and Polyclonal Antibodies to 14-3-3 Proteins no

E-056-1990/1 Antigenic Protein Of Borrelia Burgdorferi yes

E-059-1990/0 Versatile Reagent For Detecting Murine Leukemia Viruses no

E-086-1999/0 Molecular Diagnosis of Disseminated Candida albicans Infection Using Hemoglobin-Response Gene

yes

E-091-1999/0 HSV-2 Diagnostic yes

E-093-2000/0 Method of Diagnosing Multidrug Resistant Tuberculosis yes
























11

E-127-1988/0; E-145-1989/0

Adhesion Molecules (Carbohydrate Receptors) For Pathogenic Bacteria And Fungi

no

E-134-1994/0 Hepatitis C Virus Core Peptide For Stimulation Of Cytotoxic T Lymphocytes

no

E-141-1992/2 Recombinant Proteins Of A Pakistani Strain Of Hepatitis E And Their Use In Diagnostic Methods And Vaccines

yes

E-146-2002/0 Methods and Compositions to Detect Nucleic Acid yes

E-150-1994/0 Hepatitis A Virus Receptor And Methods Of Use yes

E-152-2009/0 qPCR Assay for Detection of JC Virus yes

E-176-2003/0 Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria

no

E-184-2004/0 A Novel Amplification Method Permits Pathogens to be Detected with Microarrays

yes

E-196-1989/0 Nucleotide, Deduced Amino Acid Sequence, Isolation And Purification Of Heat-Shock Chlamydial Proteins

yes

E-206-2006/0 Oligo Microarray for Detection of All Known Mammalian and Avian Pathogenic Viruses

yes

E-208-2006/0 Microarray for Detection and Subtyping of Human Influenza Viruses no

E-209-1997/0 Delayed Progression To AIDS By A Missense Allele Of The CCR2 Gene

yes

E-223-2002/0 Factors That Bind Intestinal Toxins no

E-226-1989/0 Specific And Sensitive Diagnostic Test For Lyme Disease yes

E-228-2003/1 Soluble SARS Coronavirus Spike Protein (S Protein) yes


no

E-238-2003/0 Detection and Identification of Mycobacterium Using SecA yes





























12

E-238-2009/0 Identification of Recent HIV-1 Infection by Genotypic Analysis for Treatment Strategy

yes

E-259-2004/0; E-259-2004/1

HIV-1 Infection Detection Assay for Seroconverted HIV-1 Vaccine Recipients

no

E-263-2003/0 Immunogenic T Cell Targets in Autoimmune Hepatitis and Methods of Use

no

E-276-2003/0 HIV-Dependent Expression Vector no

E-278-1999/0 Detection and Identification of Mycobacterium Using SecA yes

E-295-2001/0 Imaging of Extracellular Proteases in Cells Using Mutant Anthrax Toxin Protective Antigens

no


yes

E-304-1998/0 Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications

yes

E-325-1983/2 Production Of Complementary DNA Representing Hepatitis A Viral Sequences By Recombinant DNA Methods And Uses Therefor

no

E-454-1986/3 Human B Lymphotropic Virus (HBLV) Isolation And Products yes

E-192-2008 Optimized Expression of IL-12 Cytokine Family no

E-258-2009 Biological/Research Material for HIV Vaccine Research no

E-052-2009 Immortalized Virus-Free Human Placental Cell Lines no

E-129-2009 A549 Cells: A Well-Characterized Lung Carcinoma Cell Line Utilized for a Variety of Scientific Studies, including Adenovirus Production and Testing

no

E-342-2008 Mast Cells Defective in the Syk Protein Tyrosine Kinase no

E-010-2008 Novel Protein Delivery System for Mammalian Cells no

E-026-2009 Recombineering Vector yes






























13

E-059-2009 RNA Nanoparticles and Methods of Use no

E-106-2009 Mouse Model of Individual Unresponsive to Interferon no

E-202-2008 A Novel Treatment for Malarial Infections no

E-249-2007 A Unique Infectious Hepatitis C Virus Clone, Strain HC-TN (genotype 1a)

no

E-192-2008/1 Optimized Expression of IL-12 Cytokine Family yes

E-331-2007/2 Viral Inactivation Using Crosslinkers and Detergents no

E-260-2009/0 Biological/Research Material for H1N1 Influenza Virus Vaccine Research

no

E-258-2009/0 Biological/Research Material for HIV Vaccine Research no

E-276-2007/1 Neutralization of Hepatitis C Virus (HCV) no

E-050-2008/2 Poultry Influenza Vaccine no

E-077-2008 HPV Virus-Like Particles for Delivery of Gene-Based Vaccines no
















14

Cancer Biomarker-related Technologies


E-002-1993/0 Colon Mucosa Gene Having Down-Regulated Expression In Colon Adenomas And Adenocarcinomas

yes

E-002-2001/0 Tumor Antigen Homologous to Poly(A) Polymerase no

E-003-1991/0 Methods of Screening for Risk of Cancer Using Human Lactoferrin DNA Probe or Primer

yes

E-008-2008/0 Diagnosis and Treatment of Barrett's Esophagus and Associated Esophageal Adenocarcinoma

no

E-011-1998/0 Mammalian Selenoprotein Differentially Expressed in Tumor Cells yes

E-013-2002/0 Humanized Anti-TAG 72 CC49 for Diagnosis and Therapy of Human Carcinomas

no

E-014-2002/0 Neural Crest-Melanocyte cDNA Based Microarray Analysis for Human Skin Pigmentation Research

yes

E-018-1997/0 AIB-1, A Steroid Receptor Co-Activator Amplified In Breast And Ovarian Cancer

yes

E-018-2005/2 Diagnosing and Treating Cancer Using beta-Catenin Splice Variants yes

E-025-2009/0 Ratio Based Biomarkers for the Prediction of Cancer Survival no

E-028-1999/0 Immunogenic Peptides and Methods of Use for Treating Prostrate and Uterine Cancers

yes

E-029-1990/0; E-029-1990/1

Hepatocellular Carcinoma Oncogene yes

E-041-2005/0 Methods for Detecting Progression of Low Grade Cervical Dysplasia yes

E-042-1998/0 DLC-1 Gene Deleted in Cancers yes

E-042-2009/0 Immunogenic Peptide from NGEP Protein for Developing Prostate Cancer Vaccines

no


























15

E-044-1991/2 Truncated Hepatocyte Growth Factor Variants yes

E-046-1991/3 Met Proto-Oncogene and a Method for Predicting Breast Cancer Progression

yes

E-051-2003/0 Recombinant Immunotoxin and Use in Treating Tumors no

E-053-2001/0 PRAC & PRAC-Y: Small Nuclear Proteins Found in Prostate and Colon Cancer, and Uses Thereof

no

E-053-2009/0 Diagnostic Markers for Melanoma yes

E-057-1994/2 gp100 Cancer Antigens no

E-057-2006/0 Autoantibody Screening for Cancer Diagnosis no

E-060-2007/0; E-061-2007/0

Diagnostic Ovarian Cancer Biomarkers yes

E-065-2002/0 ELISA Assay of Serum Soluble CD22 to Assess Tumor Burden/Relapse in Subjects with Leukemia and Lymphoma

no

E-065-2008/0 Association of the ECHDCI/RNF146 Gene Region on Human Chromosome 6q with Breast Cancer Risk and Protection

yes

E-074-2007/0 Human T-box Transcription Factor Brachyury as a Target for Cancer Immunotherapy: Identification of Epitopes of Human Brachyury as Targets for T-cell Mediated Lysis of Tumors

no

E-081-2004/2 Serum Autoantibody for Cancer Diagnostics no

E-082-2005/0; E-082-2005/2

Sipa-Gene and Sipa-1 Inhibitor for the Diagnosis and Treatment of Metastatic Cancer

yes

E-083-2007/0 SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer

yes

E-084-1991/1 Antibodies and Polypeptides Specific to AAMP-1: Diagnostic and Therapeutic Uses Thereof

no

E-089-2009/0 Immunogenic Tumor-associated Antigen SPANX-B for Selective Cancer Immunotherapy

no

E-091-2002/0 Zap70 Protein Expression as a Marker for Chronic Lymphocytic Leukemia (CLL)

no































16

E-093-2007/0 Extracellular Matrix Gene Chips to Detect Metastatic Tumors no

E-106-2005/0 Identification of Biomarkers by Serum Protein Profiling no

E-117-2006/0 Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms

no

E-118-2005/0 A Gene Therapy to Treat Lung Cancer yes

E-118-2009/0 Novel Diagnostic and Therapeutic Biomarkers for Squamous Cell Carcinomas

yes

E-122-2006/0 Agonist Epitopes for Renal Cell Carcinoma no

E-124-2004/0; E-124-2004/1

Diagnostic Tool for Diagnosing Benign Versus Malignant Thyroid Lesions

no

E-125-2006/1 Extracellular Matrix/Metastasis Modifier Genes as a Method for Characterization and Prevention of Metastatic Tumor

yes

E-128-2004/0; E-128-2004/1

Cytonectin, Cytonectin Gene and Cytonectin Inhibitors and Binding Ligands and Their Use in the Diagnosis and Treatment of Disease

yes

E-132-2006/0; E-132-2006/1

A New Method for Improving the Therapeutic Efficacy of L-Asparaginase in Multiple Types of Cancer

no

E-137-1990/0 Monoclonal Antibodies Specific for Human Thymidylate Synthase no

E-138-2000/0 Tumor Markers in Ovarian Cancer no

E-138-2001/0 Use of Semenogelin in the Diagnosis, Prognosis, and Treatment of Cancer

no

E-139-2005/0 Identification of a Novel Folliculin Interacting Protein, FNIP-1 no

E-142-1990/2 Autotaxin: Motility Stimulating Protein Useful in Cancer Diagnosis and Therapy

no

E-142-2007/0 A MicroRNA Profile for Androgen Responsive Prostate Cancer no

E-152-2002/0; E-152-2002/1

Quantitative Assay of the Angiogenic and Antiangiogenic Activity of a Test Molecule

no
























http://www.ott.nih.gov/db/abstxt243.html





17

E-161-2000/0 XAGE-1, A Gene Expressed in Multiple Cancers and Uses Thereof yes

E-163-2009/0 B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia

no

E-165-2001/0 Maxp1, A New Tumor Suppressor Regulated by Ras no

E-171-2009/0 Improved Antibodies Against ErbB4/Her4 no

E-173-1998/0 Assay for the Detection of a Variety of Tumors in Biological Specimens

no

E-175-2008/0 Over-expression and Mutation of a Tyrosine Kinase Receptor FGFR4 in Tumors

yes

E-183-1999/0 Human p53 Mutations and a Genetic System in Yeast for Functional Identification of Human p53 Mutations

yes

E-184-1993/0 ERBB2 Promoter Binding Protein In Neoplastic Disease yes

E-190-2002/2 Identification of Novel Birt-Hogg-Dubé (BHD) Gene yes

E-192-2004/0 Compositions and Methods for Diagnosis and Treatment of Chemotherapy-Resistant Neoplastic Disease

no

E-192-2007/0 A Molecular Grading System for Ductal Carcinoma In Situ (DCIS) of the Breast: A New Molecular Diagnostics to Determine Disease Stages of DCIS

yes

E-194-1998/0 Calcium Channel Compositions and Methods of Use Thereof yes

E-196-2001/0 Use of Interferon-Inducible 2',5'-Oligoadenylate-Dependent RNase in the Diagnosis, Prognosis, and Treatment of Prostate Cancer

yes

E-201-1992/0 Monoclonal Antibody Specific to Prostate Cells no

E-201-2006/1 Diagnostic and Therapeutic Strategies for Metastatic Hepatocellular Carcinoma by Targeting Osteopontin

no

E-207-2006/0 Novel Monoclonal Antibody Microarray no

E-210-2005/0 Mitotic Spindle ASPM as a Diagnostic Marker for Neoplasia and Uses Thereof

no






























18

E-215-2007/0 Methods for Determining Hepatocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells

no

E-215-2008/0 Prognostic Test for Breast Cancer Based on a 12 Gene Expression Signature

no

E-218-1992/0 Novel FUSE-Binding Protein And cDNA yes

E-221-1989/0; E-221-1989/1

Novel Epidermal Growth Factor Receptor (ErbB-3) And Antibodies yes

E-225-2001/0 MRP8, A Member of the ABC Transporter Superfamily Highly Expressed in Breast Cancer, and Uses Thereof

yes

E-227-2001/0 Brother of the Regulator of Imprinted Sites (BORIS) yes


no

E-233-2002/0 Method of Distinguishing Epithelioid Melanoma from Fibroblastoid Melanoma

no

E-234-2003/0; E-108-2004/0

Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas

no

E-237-2000/0 RASS1: A Novel Tumor Suppressor Gene Activated by Ras to Promote Apoptosis

yes

E-237-2006/0 ABCB1 Genotyping to Predict Paclitaxel Toxicity yes

E-239-2005/0 Method for Promoting Stem Cell Proliferation and Survival no

E-244-2002/0 Glioma-Selective Polypeptides, Alone or Coupled to a Therapeutic/Diagnostic Agent, Compositions Comprising Same, and Uses Thereof

no

E-248-2002/0 Methods and Compositions for the Diagnosis of Neuroendocrine Lung Cancer

no

E-253-1993/0 Self-Assembling Recombinant Papillomavirus Capsid Proteins no

E-253-1997/0 PB39, A Novel Isolated Complete cDNA Whose Function is Dysregulated in Prostate Cancer

no

E-256-2008/0 Gene Expression Profiling for Prognosis of a Non-Hodgkin Lymphoma

no
































19

E-258-2005/0 Method for Determining Redox Status of a Tissue no

E-259-1998/2 Humanized Anti-Carcinoma CC49 Monoclonal Antibodies no

E-259-2000/0 Protein Kinase A and the Carney Complex yes

E-261-2005/0; E-261-2005/1

Sensitive Antibody-based Assay for the Measurement of c-Met Concentration Shed in Bodily Fluids Useful in the Diagnosis and Prognosis of Cancer

no

E-262-2000/0; E-262-2000/1

SH2 Domain Binding Inhibitors no

E-263-2006/1 Methods of Determining the Prognosis of an Adenocarcinoma no

E-265-1997/0 Cancer Peptides of NY-ESO-1/CAG-3 yes

E-265-2007/0 Telomerase Suppressor Compositions and Methods for Diagnosis and Treatment of Cancer

yes

E-269-2003/0 Composition for Detecting the Response of Rectal Adenocarcinomas to Radiochemotherapy

yes

E-282-2007/0 TGF-beta Gene Expression Signature in Cancer Prognosis no

E-283-2008/0 Method for Detection of Cancer Based on Spatial Genome Organization in the Cell Nucleus

no

E-285-2006/2 New Tumor Endothelial Markers: Genes that Distinguish Physiological and Pathological Angiogenesis

no

E-286-2000/0 Histone Deacetylase Inhibitors in Diagnosis and Treatment of Thyroid Neoplasms

no

E-287-2004/1 Novel Diagnostics and Therapeutics for Various Hematologic Malignancies: Monoclonal Antibodies to Members of Fc receptor-like (FCRL) Proteins

no

E-290-2000/0 A Novel, Clinically Validated, Efficient and Non-Invasive In Vitro Diagnostic and Prognostic Test for Cancer

no

E-293-2006/0 Megakaryocyte Potentiation Factor as a New Serum Tumor Marker for Mesothelioma

no

E-295-2009/0 Prediction of Immune Response Outcomes to Keyhole Limpet Hemocyanin (KLH) Treatment

no
































20

E-300-2001/0 Tumor Suppressor Genes yes


yes

E-307-2005/0 Use of CYP1B1*3 Genotyping to Predict Survival to Docetaxel Treatment in Androgen-Independent Prostate Cancer

yes

E-310-2001/0 Identification of Ovarian Cancer Tumor Markers and Therapeutic Agents

no

E-314-2008/0 Inflammatory Genes and MicroRNA-21 as Biomarkers for Colon Cancer Prognosis

no

E-317-2008/0 Identification of Renal Cell Carcinoma Biomarkers no

E-323-2003/0 Minimally Immunogenic Variants of SDR-Grafted Humanized Antibody CC49 and Their Use

no

E-324-2001/2 Selections of Genes and Methods of Using the Same for Diagnosis and for Targeting the Therapy of Select Cancers

no

E-328-2007/0 Identification of Persons Likely to Benefit from Statin Mediated Cancer Prevention by Pharmacogenetics

yes

E-340-2008/0 Methods for Identifying Breast Cancer Patients for Therapy with mTOR Inhibitors

yes

E-344-2001/0 The Ovachip: A Clinically Useful cDNA Array for Differential Diagnosis of Ovarian Cancer

no





















Documents

National Institutes of Health - NIH Office of …...Angiogenesis no E-010-2004/2 Modulating P38 Kinase Activity no E-014-2002/0 Neural Crest-Melanocyte cDNA Based Microarray Analysis